McLauchlan L, Lancaster K, Kearnes M, Mellor R, Ritter A. "It's professional but it's personal": participation, personal connection, and sustained disagreement in drug policy reform. Int J Drug Policy. 2022 Dec;110:103903. doi: 10.1016/j.drugpo.2022.103903
Gourdet C, Giombi KC, Kosa K, Wiley J, Cates S. How four U.S. states are regulating recreational marijuana edibles. Int J Drug Policy. 2017 May;43:83-90. doi: 10.1016/j.drugpo.2017.01.018.
Kosa KM, Giombi KC, Rains CB, Cates SC. Consumer use and understanding of labelling information on edible marijuana products sold for recreational use in the states of Colorado and Washington. Int J Drug Policy. 2017 May;43:57-66. doi: 10.1016/j.drugpo.2017.01.006
Mauskopf J, Chirila C, Birt J, Boye KS, Bowman L. Drug reimbursement recommendations by the National Institute for Health and Clinical Excellence: have they impacted the National Health Service budget? Health Policy (New York). 2013 Apr 1;110(1):49-59.
Richter A, Hicks KA, Earnshaw SR, Honeycutt AA. Allocating HIV prevention resources: a tool for state and local decision making. Health Policy (New York). 2008 Sep 1;87(3):342-9.
Lovas K, Kalo Z, McKenna SP, Whalley D, Pentek M, Genti G. Establishing a standard for patient-completed instrument adaptations in Eastern Europe: experience with the Nottingham Health Profile in Hungary. Health Policy (New York). 2003 Jan 1;63(1):20.
McKenna SP, Whalley D. Assessment of biotechnology drugs: what are the issues? Letter to the editor. Health Policy (New York). 1999 Nov;49(3):195-7. doi: 10.1016/S0168-8510(99)00055-X